Barbier, Michaela Carla; Fengler, Alicia; Pardo, Esther; Bhadhuri, Arjun; Meier, Niklaus; Gautschi, Oliver (2023). Cost Effectiveness and Budget Impact of Nivolumab Plus Ipilimumab Versus Platinum Plus Pemetrexed (with and Without Bevacizumab) in Patients with Unresectable Malignant Pleural Mesothelioma in Switzerland PharmacoEconomics, 41(12), pp. 1641-1655. Springer 10.1007/s40273-023-01305-3
|
Text
s40273-023-01305-3.pdf - Published Version Available under License Creative Commons: Attribution-Noncommercial (CC-BY-NC). Download (1MB) | Preview |
Background Malignant pleural mesotheliomas (MPMs) are aggressive and often unresectable. In the past, chemotherapy was the standard for palliative treatment. However, immunotherapy with nivolumab+ipilimumab has recently received marketing approval. Objectives This study evaluated the cost effectiveness of nivolumab+ipilimumab versus pemetrexed+platinum (with/without bevacizumab) for Swiss patients with unresectable MPM, overall and by histological subtype. Methods We developed a three-state Markov cohort model with a cycle length of 1 month, a 30-year time horizon, and a discount rate of 3% per year for costs and benefits. The model included the updated survival and treatment-dependent utility results from the Checkmate-743 and MAPS registration trials. A Swiss statutory health insurance perspective was considered with unit costs for 2022 from publicly available and real-world sources. We assumed a willingness-to-pay (WTP) threshold of CHF100,000/QALY. Model robustness was explored in sensitivity and scenario analyses. Results Compared with chemotherapy, nivolumab+ipilimumab incurred additional costs of CHF109,115 and 0.57 additional quality-adjusted life-years (QALYs), yielding an incremental cost-effectiveness ratio (ICER) of CHF192,585/QALY (i.e. USD201,829/QALY) gained. Relative to their 2022 list price, nivolumab+ipilimumab may be cost effective if priced at 48% across all histologies. Assuming cisplatin-based instead of carboplatin-based chemotherapy reduced the ICER to CHF158,911/QALY (i.e. USD166,539/QALY). For the non-epithelioid subtype, nivolumab+ipilimumab was cost effective compared with chemotherapy (ICER of CHF97,894/QALY, i.e. USD102,593/QALY). Chemotherapy+bevacizumab was often a dominated strategy or would require a bevacizumab cost reduction to 28%. Conclusions Our model projected nivolumab+ipilimumab to be cost effective for the non-epithelioid subtype but not for all histologies. Substantial discounts for nivolumab+ipilimumab would be necessary to achieve cost effectiveness for all histologies.
Item Type: |
Journal Article (Original Article) |
|---|---|
Division/Institute: |
School of Health Professions School of Health Professions > Institute of Health Economics and Health Policy |
Name: |
Barbier, Michaela Carla; Fengler, Alicia; Pardo, Esther; Bhadhuri, Arjun; Meier, Niklaus and Gautschi, Oliver |
ISSN: |
1170-7690 |
Publisher: |
Springer |
Language: |
English |
Submitter: |
Niklaus Meier |
Date Deposited: |
13 Nov 2023 09:40 |
Last Modified: |
13 Nov 2023 09:40 |
Publisher DOI: |
10.1007/s40273-023-01305-3 |
ARBOR DOI: |
10.24451/arbor.20301 |
URI: |
https://arbor.bfh.ch/id/eprint/20301 |
Actions (login required)
 |
View Item |